Publication Name	World Journal of Virology
Manuscript ID	75875
Country	United States

Received	2022-02-19 20:11
Peer-Review Started	2022-02-19 20:13
To Make the First Decision
Return for Revision	2022-05-12 08:13
Revised	2022-05-15 15:24
Second Decision	2022-07-13 02:49
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-07-18 00:03
Articles in Press	2022-07-18 00:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-07-18 07:32
Publish the Manuscript Online	2022-07-22 07:22

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Cautious optimism in anticipation of hepatitis B curative therapies
Manuscript Source	Invited Manuscript
All Author List	Alla Turshudzhyan and Micheal Tadros
Funding Agency and Grant Number
Corresponding Author	Alla Turshudzhyan, DO, N/A, Department of Medicine, University of Connecticut, 263 Farmington Avenue , Farmington, CT 06030-1235, United States. turshudzhyan@uchc.edu
Key Words	Hepatitis B; Hepatitis B virus; Hepatitis B virus entry inhibitor; Bulevirtide; Transcription activator-like effector nucleases; Zinc-finger nucleases; Clustered regularly interspaced short palindromic repeats-associated 9; Nucleocapsid assembly modulators; Hepatitis B virus transcription inhibitors; Hepatitis B surface antigen release inhibitors
Core Tip	Hepatitis B could become a curable disease in the near future. As our understanding of pathophysiology of hepatitis B infection advances, more therapeutic targets are becoming available. Many new therapies have only been investigated in small groups of patients with low viral load and without hepatotoxic injury or in patients with hepatitis D co-infection, which makes it difficult to predict efficacy and side effect profile when applied to the population of interest. Larger clinical trials in hepatitis B patients are needed to further investigate the emerging new therapies, so that more patients can safely benefit from them.
Publish Date	2022-07-22 07:22
Citation	Turshudzhyan A, Tadros M. Cautious optimism in anticipation of hepatitis B curative therapies. World J Virol 2022; 11(4): 212-215
URL	https://www.wjgnet.com/2220-3249/full/v11/i4/212.htm
DOI	https://dx.doi.org/10.5501/wjv.v11.i4.212

Full Article (PDF)	WJV-11-212.pdf
Full Article (Word)	WJV-11-212.docx
Manuscript File	75875_Auto_Edited-YJM-LS.docx
Answering Reviewers	75875-Answering reviewers.pdf
Audio Core Tip	75875-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	75875-Conflict-of-interest statement.pdf
Copyright License Agreement	75875-Copyright license agreement.pdf
Peer-review Report	75875-Peer-review(s).pdf
Scientific Editor Work List	75875-Scientific editor work list.pdf